KeraThin is a medical device company focused on tools and treatments of diabetes related foot disease. Medicare spent $350 million for nail debriding (removing infected nail layers). The PodiaPro Nail Debridement System© from KeraThin enables safer nail debridement for patients with onychomycosis; commonly called toenail fungus (TNF). Diabetics are particularly prone to onychomosis infection. Athletes and other populations are also vulnerable, as are people who elect to use nail coverings with nail adhesives. Diabetes affects an increasing portion of the population because of obesity and the overall aging of the population. In its first market entry, KeraThin will work with podiatrists to provide new tools and therapeutic options for these patients. The company expects to introduce an oscillating nail trimming tool for use in the podiatrist office and a lower-powered tool enabling patients to maintain their nails at home. Both tools utilize disposable pads. The home tool will incorporate a topical medication for quicker results in attacking the fungus. Management believes that no one company is focused on the overall care of diabetic foot disorders or the podiatric market.